Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.38 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.37 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.37 |
| ▸ | LRRK2 | Q5S007 | 5/20 | 0.37 |
| ▸ | PIK3C3 | Q8NEB9 | 5/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | KDM5A | P29375 | 1/20 | 0.33 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23629224 | 0.80 | KDM5A (0.45) | KDM4ELMNAKDM5AKDM5B | |
| SCHEMBL27009072 | 0.79 | PSMD14 (0.44) | SLC40A1PKN1PKN2KDM4EMEN1 | |
| SCHEMBL23629272 | 0.79 | KDM4E (0.44) | SLC40A1PKN1PKN2KDM4EKDM5A | |
| SCHEMBL23629249 | 0.78 | PTPN11 (0.40) | SLC40A1PKN1PKN2PIK3C3KDM4E | |
| SCHEMBL8568156 | 0.69 | PREP (0.47) | SLC40A1KDM4EMEN1KMT2AGLA | |
| SCHEMBL23629248 | 0.69 | MEN1 (0.35) | SLC40A1LRRK2PIK3C3MEN1KMT2A | |
| SCHEMBL3466096 | 0.69 | TSHR (0.32) | KDM4EMEN1KMT2ALMNA | |
| SCHEMBL14762924 | 0.69 | CCR1 (0.40) | LRRK2SMN1; SMN2 | |
| SCHEMBL29568444 | 0.66 | LMNA (0.46) | SLC40A1PIK3C3KDM4ELMNA | |
| SCHEMBL286535 | 0.65 | NCF1 (0.41) | MEN1KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12371430-B2 | 5-morpholin-4-yl-pyrazolo[4,3-b]pyridine derivatives | MERCK PATENT GMBH (DE) | 2025-07-29 | — | — | US | claimed |
| US-20210355123-A1 | 5-Morpholin-4-yl-pyrazolo[4,3-b]pyridine derivatives | MERCK PATENT GMBH (DE) | 2021-11-18 | — | — | US | claimed |
| EP-3846904-A1 | 5-MORPHOLIN-4-YL-PYRAZOLO[4,3-B]PYRIDINE DERIVATIVES | Merck Patent GmbH (DE) | 2021-07-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210355123-A1 | 5-Morpholin-4-yl-pyrazolo[4,3-b]pyridine derivatives | ATR, CDK1, CDKN1A | SLC40A1 4240/4885PKN1 278/4885PKN2 107/4885 |
| US-12371430-B2 | 5-morpholin-4-yl-pyrazolo[4,3-b]pyridine derivatives | ATR, CDK1, CDKN1A | SLC40A1 4240/4885PKN1 278/4885PKN2 107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.